Celgene (CELG) Issues Encouraging Update on REVLIMID Phase 2/3 in Relapsed/Refractory DLBCL
Tweet Send to a Friend
Celgene (NASDAQ: CELG) announced that results were presented from a phase II/III study (DLC-001) of REVLIMID (lenalidomide) compared with investigators’ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
